Progyny PGNY 深 滬
等待開盤 02-06 09:30:00 美东时间
22.265
-0.505
-2.22%
華盛通- 最 高23.565
- 今 開22.78
- 成交量 94.29万股
- 最 低 22.135
- 昨 收 22.77
- 總市值 19.09亿
- 52周最高 28.75
- 市盈率 靜 39.11
- 換手率 0.00%
- 52周最低 17.9765
- 委 比 -53.42%
- 總股本 8571.80万
- 歷史最高 68.32
- 量 比 0.70
- 振 幅 6.28%
- 歷史最低 13.29
- 每 手 1
- 風險率 1.94%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多U.S. RESEARCH ROUNDUP-IBM, KLA, WEX
U.S. RESEARCH ROUNDUP-IBM, KLA, WEX Jan 21 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including IBM, KLA and WEX, on Wednesday. HIGHLIGHTS * IBM IBM.N : JP Morgan raises target price to $312 from $290 * KLA Corp KLAC.O : Deut
01-21 16:26
美股大行评级 | 存储再获大行看好！花旗、瑞银和美银齐上调西部数据、希捷科技等公司目标价；PNC金融服务获6家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Soleno Therapeutics"买入"评级，目标价从110美元升至120美元；富国银行：维持Soleno Therapeutics"超配"评级，目标价从106美元升至114美元
01-21 11:42
This Intel Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a comple...
01-20 19:28
Citizens Upgrades Progyny to Market Outperform, Announces $30 Price Target
Citizens analyst Constantine Davides upgrades Progyny (NASDAQ:PGNY) from Market Perform to Market Outperform and announces $30 price target.
01-20 18:22
Progyny to Discuss Updated Financial Expectations at Upcoming JP Morgan Healthcare Conference
Progyny, Inc. anticipates fourth quarter and full year 2025 results to be slightly above previously provided financial guidance, with revenue, net income, and Adjusted EBITDA expected to exceed November projections. CEO Pete Anevski highlighted strong member engagement as a key factor. The company will present at the JP Morgan Healthcare Conference on January 13, 2026, with executives discussing updated expectations. A live audiocast and replay w...
01-12 13:00
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
Keybanc Maintains Overweight on Progyny, Raises Price Target to $32
Keybanc analyst Scott Schoenhaus maintains Progyny (NASDAQ:PGNY) with a Overweight and raises the price target from $30 to $32.
01-08 22:32
Cheap smaller cap stocks that promise acceleration in fundamentals – BofA
BofA analysts outlined a list of inexpensive small- and mid-cap stocks with accelerating fundamentals. These are Russell 2000 (IWM) stocks that have cheap valuations along with positive revisions and ...
2025-12-20 00:57
美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
2025-12-10 10:33
Barclays Initiates Coverage On Progyny with Overweight Rating, Announces Price Target of $29
Barclays analyst Glen Santangelo initiates coverage on Progyny (NASDAQ:PGNY) with a Overweight rating and announces Price Target of $29.
2025-12-10 00:13
